All News

2019

December

Media Release / Dec 02, 2019

Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms

Read More

November

Novartis Stein, Switzerland
Featured News / Nov 28, 2019

Novartis opens facility for innovative cell and gene therapies in Switzerland

New cell and gene manufacture in Stein offers hope for patients around the globe.

Read More
Media Release / Nov 24, 2019

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

Read More
Media Release / Nov 21, 2019

Novartis launches Innovation Prize for Assistive Tech to encourage new technologies that address unmet needs of the multiple sclerosis community

Read More
Media Release / Nov 17, 2019

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

Read More
Media Release / Nov 15, 2019

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

Read More
Media Release / Nov 15, 2019

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)

Read More
Preterm infant in the neonatology intensive care unit is checked regularly for retinopathy of prematurity (ROP)
Story / Nov 13, 2019

Visionary: Silke Mader has a vision for the care of premature infants and their parents

Caring for a baby with retinopathy of prematurity (ROP) has never been easy. But mother and social visionary Silke Mader has made it her life’s work to ensure that parents dealing with ROP and other complications today get more support than she did.

Read More
Media Release / Nov 13, 2019

Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

Read More
Media Release / Nov 12, 2019

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More